albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study. (PubMed, EClinicalMedicine) - P2 | "This work is supported by the Beijing Municipal Science & Technology Commission (No. Z231100007223002)."

Journal • P2 data • Endocrine Cancer • Hematological Disorders • Leukopenia • Neuroendocrine Carcinoma • Neutropenia • Oncology • Solid Tumor

A Prospective Observational Study of Atezolizumab plus Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer: First Analysis of JBCRG-C08/ATTRIBUTE (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Observational data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Safety Run-In Phase of the ATRiBRAVE trial: a Phase II Study Evaluating Ceralasertib Priming Followed by Durvalumab/Nab-Paclitaxel to Restore Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer (TNBC) (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Metastases • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Efficacy and safety of Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-blind Phase III study (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor

Cryotherapy combined with compression gloves and socks therapy reduce nab-paclitaxel-induced peripheral neuropathy in breast cancer patients undergoing neoadjuvant chemotherapy: a multicenter randomized controlled trial (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Breast Cancer • Oncology • Solid Tumor

Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis. (PubMed, ESMO Open) - "5-FU + Nal-IRI showed a modest yet statistically significant survival advantage compared with FOLFOX/XELOX in patients with metastatic PDAC previously treated with GemNab, despite being associated with a higher incidence of adverse events. None the less, the selection of second-line therapy should be guided by a balanced evaluation of both efficacy and toxicity profiles."

Journal • Hematological Disorders • Oncology • Pain • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thrombocytopenia

Toward a new standard: Sequential multi-agent neoadjuvant chemotherapy in resectable pancreatic cancer. (PubMed, Cancer Cell) - "A randomized trial by Bai et al. in Cancer Cell demonstrates that sequential neoadjuvant gemcitabine/nab-paclitaxel followed by mFOLFIRINOX significantly improved event-free survival compared with upfront surgery, supporting a shift toward a sequential neoadjuvant approach in this setting."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

Single-cell profiling unveils the immuno-favorable tumor microenvironment remodeling after successful neoadjuvant therapy for advanced gallbladder cancer. (PubMed, Int J Surg) - "This study suggested the potential efficacy of NAT in advanced GBC and revealed alterations in the TME following treatment. The findings provided insights into the mechanisms underlying NAT responses and offered valuable directions for optimizing therapeutic strategies in GBC."

Biomarker • Journal • Gallbladder Cancer • Oncology • Solid Tumor • CAFs • CCL19 • CD8 • CXCL12 • GZMB

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. (PubMed, Redox Biol) - P1/2 | "High-dose AA with NABPLAGEM was tolerable in patients with advanced PDAC but did not improve disease response compared to historical data for chemotherapy alone. A separate study suggests AA may enhance gemcitabine and nab-paclitaxel efficacy without cisplatin. AA and cisplatin may have overlapping DNA-damaging effects, or differences in AA dosing frequency and exposure may influence outcomes - variables to consider in future trials."

Journal • P1 data • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Neutropenia • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thrombocytopenia • KRAS • SLC2A1

PHASE 3 ROSELLA (GOG-3073, ENGOT-OV72) TRIAL OF RELACORILANT + NAB-PACLITAXEL VS NAB-PACLITAXEL IN PLATINUM-RESISTANT OVARIAN CANCER: PRIMARY RESULTS AND OUTCOMES IN OLDER PATIENTS (IGCS 2025) - "The addition of relacorilant to nab-paclitaxel showed a statistically significant improvement in PFS by BICR and a clinically meaningful benefit in OS at the interim analysis (Table). Patients aged ≥65 were heavily pretreated, had advanced disease, and were similarly distributed between treatment arms (38.3% vs 41.5%). The addition of relacorilant was associated with a 39% reduction in the risk of progression in this subgroup (PFS by BICR: HR 0.61 [95% CI 0.40-0.94] P=0.0247)."

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Safety, feasibility, and preliminary efficacy of albumin-bound paclitaxel as monotherapy and in combination with carboplatin delivered by blood-brain barrier opening using a skull-implantable ultrasound: Preliminary results of a Phase I-II trial in recurrent glioblastoma. (WFNOS 2025) - P1/2 | "Delivery of ABX plus carboplatin using LIPU/MB is well-tolerated. TGR in sonicated brain appears to predict OS in patients treated with ABX with or without carboplatin delivered by LIPU/MB. Early signs of efficacy suggest that this combination might be superior to ABX monotherapy."

Clinical • Combination therapy • Monotherapy • P1/2 data • Brain Cancer • Glioblastoma • Hematological Disorders • Neutropenia • Solid Tumor

Safety, feasibility, and preliminary efficacy of albumin-bound paclitaxel as monotherapy and in combination with carboplatin delivered by blood-brain barrier opening using a skull-implantable ultrasound: Preliminary results of a Phase I-II trial in recurrent glioblastoma. (WFNOS 2025) - P1/2 | "Delivery of ABX plus carboplatin using LIPU/MB is well-tolerated. TGR in sonicated brain appears to predict OS in patients treated with ABX with or without carboplatin delivered by LIPU/MB. Early signs of efficacy suggest that this combination might be superior to ABX monotherapy."

Clinical • Combination therapy • Monotherapy • P1/2 data • Brain Cancer • Glioblastoma • Hematological Disorders • Neutropenia • Solid Tumor

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results (DGHO 2025) - P3 | "Preliminary safety data, including 30 min infusion time with D are reported. Participants (pts) received D 1500 mg (first infusion: 60 min; subsequent infusions: 30 min) with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin, carboplatin, cisplatin (cis), tegafur-gimeracil-oteracil (S-1), cis + S-1, or cis + nab-paclitaxel). No difference in infusion-related safety between 30 and 60 min infusion time was observed. No new safety signals were seen with the addition of D to other chemotherapy regimens beyond TOPAZ-1 regimens.Previously presented at ESMO ASIA 2024, Abstract 133O, Do-Youn Oh et. al."

Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Treatment and Outcomes in Elderly Patients (≥80 years) with Pancreatic Ductal Adenocarcinoma: Real-World Data from the Single-Center Registry PANDA (DGHO 2025) - "First-line chemotherapy was administered to 43 patients (49.4%); 69.8% (n=30) received gemcitabine monotherapy (Gem), 18.6% (n=8) Gem plus nab-paclitaxel (NabP) and 4.7% (n=2) FOLFOX (5-FU/leucovorin/oxaliplatin)... Patients ≥ 80 years represent a clinically significant yet heterogeneous subgroup in PDAC. Despite limited chemotherapy administration in elderly, survival outcomes remain poor. As cancer incidence in the elderly population is expected to rise, RWD from cancer centers will be critical for guiding optimized and potentially more aggressive treatment approaches in this patient group.Figure 1:"

Clinical • Real-world • Real-world evidence • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

"Retinoic acid-based treatment and response biomarkers in pancreatic cancer" (DGHO 2025) - "To support future trials on RA treatment in PDAC, we studied the clinical impact of these biomarkers in PDAC patients and explored ATRA effect in patient-derived organoids (PDOs). We prospectively enrolled patients with advanced PDAC receiving gemcitabine (GEM) +/- nab-paclitaxel (NAB-P). Our preclinical data support the repurposing of ATRA, which has a favorable toxicity profile, to potentiate GEM efficacy among PDAC patients. Our clinical data indicate that vitamin A and PTX3 are suitable response biomarkers for GEM-based treatment in PDAC, potentially stratifying for the addition of RA-based treatment. Different from ctDNA, vitamin A and PTX3 may specifically reflect the effect of treatment on stromal remodeling."

Biomarker • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CA 19-9 • KRAS • PTX3

Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cancer. (PubMed, Anticancer Drugs) - "This study compared the efficacy and safety of S-1 + oxaliplatin (SOX) plus sintilimab, albumin-bound paclitaxel + oxaliplatin (P-SOX), and docetaxel + oxaliplatin + 5-fluorouracil (DOF) as neoadjuvant regimens for advanced gastric cancer...Common adverse events included grade 1-2 gastrointestinal reactions, peripheral neurotoxicity, and alopecia, with good tolerability. SOX plus sintilimab achieved the most favorable OS with comparable safety."

Journal • Alopecia • Gastric Cancer • Immunology • Oncology • Solid Tumor

HER2 inhibitor-based combination therapy for recurrent and metastatic salivary duct carcinoma in an elderly patient: a case report and literature review. (PubMed, Front Oncol) - "The patient subsequently received trastuzumab combined with low-dose nab-paclitaxel, achieving a partial response according to RECIST 1.1 criteria. At the most recent follow-up, the patient remains in stable condition. This case highlights the efficacy and safety of HER2-targeted combination therapy in elderly SDC patients, offering valuable insights into biomarker-driven personalized treatment strategies for this population."

Journal • Oncology • Salivary Gland Cancer • Submandibular Gland Cancer • HER-2

BDTX-4933-101: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (clinicaltrials.gov) - P1/2 | N=554 | Recruiting | Sponsor: Institut de Recherches Internationales Servier | Phase classification: P1 ➔ P1/2 | N=100 ➔ 554 | Trial completion date: Dec 2026 ➔ Jun 2028 | Trial primary completion date: Jun 2026 ➔ Jun 2028

Enrollment change • Monotherapy • Phase classification • Trial completion date • Trial primary completion date • Brain Cancer • Colorectal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thyroid Gland Carcinoma • BRAF • KRAS • NRAS

Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancer. (PubMed, Eur J Pharm Sci) - "To address this challenge, we report the development of a novel implantable drug delivery device that enables the localized administration of a CD40 agonist in combination with anti-PD1, doxorubicin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel)...However, the localized approach achieved equivalent or enhanced immune activation without inducing the fatal immune reactions observed with systemic dosing, suggesting that localized treatment can offer a significant therapeutic advantage. This study demonstrates that our innovative localized delivery approach has the potential to significantly improve patient outcomes by maximizing efficacy and minimizing adverse effects for this aggressive subtype of breast cancer."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8

[Translated article] Influence of age on the efficacy of immunochemotherapy in non-small cell lung cancer. (PubMed, Farm Hosp) - "Both those younger and older than 65 years benefit from immunotherapy combined with chemotherapy in the treatment of non-small cell lung cancer. Although there appears to be greater efficacy in those younger than 65 years, the influence of age is not entirely clear."

Clinical • IO biomarker • Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=120 | Active, not recruiting | Sponsor: Flemming Forsberg | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=252 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

Monotherapy • New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): results from a phase 2 study (SITC 2025) - P2 | "In Part 1, patients with nonsquamous NSCLC received SSGJ-707 at 5/10/20 mg/kg or tislelizumab with carboplatin+pemetrexed...Based on the selected dose from cohort A, Part 2 cohort B evaluated SSGJ-707 10 mg/kg or tislelizumab with carboplatin + paclitaxel or SSGJ-707 10 mg/kg + carboplatin + nab-paclitaxel in squamous NSCLC.Results At the data cutoff of July 4, 2025, 119 patients with nonsquamous NSCLC and 125 with squamous NSCLC were enrolled in Parts 1 and 2, respectively...ORRs with SSGJ-707 exceeded that of tislelizumab + chemotherapy. These results support further evaluation of SSGJ-707 10 mg/kg Q3W combined with chemotherapy in a phase 3 study in first-line NSCLC regardless of PD-L1 expression.Abstract 1328 Table 1View inline•Open as popupEfficacy and safetyAbstract 1328 Figure 1Request permissionsWaterfall plots for SSGJ-707 + chemotherapy in Part 1, Part 2 cohort A, and Part 2 cohort B"

Clinical • IO biomarker • Late-breaking abstract • Metastases • P2 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1 • PD-L1

Phase Ib/IIa Study of HCB101 Combined with Standard Therapies Demonstrates Manageable Safety and Dose-Dependent Antitumor Activity in Immunologically Cold Advanced Solid Tumors (SITC 2025) - P1, P1/2 | "Cohorts included: a) second-line (2L) GC (HCB101 plus ramucirumab and paclitaxel); and b) first-line (1L) TNBC (HCB101 plus toripalimab and nab-paclitaxel). NCT06771622Ethics Approval The study was approved by following ethics committees: 1.Cancer Hospital of Shandong First Medical University Ethics Committee; Number of theapproval: SDZLEC2024-412-04; 2.The Fifth Affiliated Hospital, Sun Yat-sen University Ethics Committee; Number of the approval:2025-Y241-3; 3.Dongguan People's Hospital Ethics Committee; Number of the approval: DRYA2025-015-B3; 4.Qilu Hospital of Shandong University Dezhou Hospital Ethics Committee; Number of the approval: 2025-003-002; 5.Binzhou Medical University Affiliated Hospital Ethics Committee; Number of the approval: 2025-011-03; Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this..."

Clinical • Late-breaking abstract • Metastases • P1/2 data • Breast Cancer • Gastric Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • CD47 • SIRPA

Circulating intermediate monocytes are elevated in pancreatic cancer after neoadjuvant chemotherapy (SITC 2025) - "While patient number is still low, it appears this effect may be more prominent in patients receiving FOLFIRINOX rather than gemcitabine/nab-paclitaxel treatment...Additional work includes an ex vivo study to culture sorted intermediate monocytes with matched extracellular fluid from patient tumors to determine if intermediate monocytes that may be recruited to tumors differentiate into pro-tumor or anti-tumor cell types.Ethics Approval This study obtained IRB approval (2505164691) by the West Virginia University Office for Human Research Protections. All patients gave informed consent prior to taking part in the study."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor • CD14